2024年12月16日 · The U.S. Food and Drug Administration’s Center for Veterinary Medicine has completed an evaluation of adverse events reported in dogs of various ages treated with Librela (bedinvetmab injection).

2024年4月26日 · Bedinvetmab is indicated for the relief of osteoarthritis pain in dogs. It is given by your veterinarian as a once-a-month subcutaneous (under the skin) injection. Dosage is determined by the dog’s weight.

Bedinvetmab, sold under the brand name Librela, is a canine monoclonal antibody used for the control of pain associated with osteoarthritis in dogs. [3] [4] [5] Librela is sponsored by Zoetis. [5] [6]

2025年1月7日 · The Food and Drug Administration (FDA) has issued a “Dear Veterinarian Letter” regarding reports of adverse events in dogs treated with Librela (bedinvetmab injection). The monoclonal antibody drug is used for the control of pain associated with osteoarthritis in dogs.

2023年5月5日 · PARSIPPANY, N.J.-- (BUSINESS WIRE)-- Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs.

2024年3月13日 · Librela™ (bedinvetmab) injection is the first and only anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy for the control of pain associated with osteoarthritis in dogs. It is an injection given to your dog once a month by …

2024年10月23日 · Bedinvetmab is available as an injectable prescription given to your dog in a veterinary clinic. How Is Bedinvetmab Used? Bedinvetmab is given to your dog as an injection underneath the...